{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T22:14:13Z","timestamp":1773353653476,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.biopha.2018.07.078","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T23:31:17Z","timestamp":1532129477000},"page":"1267-1270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Determination of gliclazide minimum concentration in type 2 diabetes mellitus patients"],"prefix":"10.1016","volume":"106","author":[{"given":"Andrzej","family":"Czyrski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matylda","family":"Resztak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadeusz","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.07.078_bib0005","series-title":"Clinical Pharmacy and Therapeutics","year":"2012"},{"key":"10.1016\/j.biopha.2018.07.078_bib0010","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/aps.2011.33","article-title":"Tissue-specific alternations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats","volume":"32","author":"Zhang","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.biopha.2018.07.078_bib0015","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF03261926","article-title":"Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs","volume":"51","author":"Dostalek","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2018.07.078_bib0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11892-014-0473-5","article-title":"Sulfonylureas: a new look at old therapy","volume":"14","author":"Thul\u00e9","year":"2014","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.biopha.2018.07.078_bib0025","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jcjd.2015.01.001","article-title":"The hypoglycemic risk of glyburide (glibenclamide) compared with modified-release gliclazide","volume":"39","author":"Clemens","year":"2015","journal-title":"Can. J. Diabetes"},{"key":"10.1016\/j.biopha.2018.07.078_bib0030","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2165\/00003495-200262090-00010","article-title":"Gliclazide modified release","volume":"62","author":"McGavin","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2018.07.078_bib0035","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1462-8902.2004.00404.x","article-title":"Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes","volume":"6","author":"Drouin","year":"2004","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2018.07.078_bib0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.diabres.2015.07.002","article-title":"Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents","volume":"110","author":"Chan","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2018.07.078_bib0045","first-page":"11","article-title":"Pharmacological and pharmaceutical profile of gliclazide: a review","volume":"1","author":"Sarkar","year":"2011","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.biopha.2018.07.078_bib0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1365-2125.2000.00162.x","article-title":"Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes","volume":"49","author":"Davis","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2018.07.078_bib0055","first-page":"215","article-title":"Use of solid phase extraction in quantitative determination of gliclazide in human serum by HPLC","volume":"42","author":"G\u0142\u00f3wka","year":"1997","journal-title":"Chem. Anal."},{"key":"10.1016\/j.biopha.2018.07.078_bib0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/bdd.303","article-title":"Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers","volume":"23","author":"Delrat","year":"2002","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.biopha.2018.07.078_bib0065","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1570-0232(02)00951-0","article-title":"A simple and sensitive HPLC method for determination of gliclazide in human serum","volume":"785","author":"Rouini","year":"2003","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.biopha.2018.07.078_bib0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0378-5173(98)00167-7","article-title":"Bioavailability of gliclazide from some formulation tablets","volume":"172","author":"G\u0142\u00f3wka","year":"1998","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2018.07.078_bib0075","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jpba.2004.02.025","article-title":"Quantification of gliclazide by semi-micro high-performance liquid chromatography: application to a bioequivalence study of two formulations in healthy subjects","volume":"35","author":"Park","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.biopha.2018.07.078_bib0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0026-0495(03)00215-4","article-title":"Gliclazide modified release: a critical review of pharmacodynamic, metabolic, and vasoprotective effects","volume":"52","author":"Schernthaner","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.biopha.2018.07.078_bib0085","first-page":"133","article-title":"24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily","volume":"27","author":"Guillausseau","year":"2001","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.biopha.2018.07.078_bib0090","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.diabres.2010.05.012","article-title":"The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial","volume":"89","author":"Zoungas","year":"2010","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2018.07.078_bib0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/dmrr.2470","article-title":"The incidence of mild and severe hypoglycemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis","volume":"30","author":"Schopman","year":"2014","journal-title":"Diabetes Metab. Res. Rev."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218310746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218310746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:29:26Z","timestamp":1750879766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218310746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":19,"alternative-id":["S0753332218310746"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.07.078","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of gliclazide minimum concentration in type 2 diabetes mellitus patients","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.07.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}